RQ 00000010

Drug Profile

RQ 00000010

Alternative Names: CJ-12433; RQ-00000010; RQ-10

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer CJ HealthCare; RaQualia Pharma
  • Class Gastrokinetics
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastro-oesophageal reflux

Highest Development Phases

  • Phase I Gastrointestinal disorders
  • Preclinical Dyspepsia

Most Recent Events

  • 20 Apr 2016 RQ 00000010 is still in phase I trials for Gastrointestinal disorders in United Kingdom
  • 20 Apr 2016 RQ 00000010 is still in preclinical trials for Dyspepsia in South Korea
  • 31 Dec 2012 Preclinical trials in Dyspepsia in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top